- EDAP, developer of promising medical devices for HIFU and ESWL treatments, has been buffeted by hospitals concentrating on treating Covid-19 patients.
- However, this looks like postponement to us, with little long-term damage to the company’s perspectives, which remain bright.
- We therefore see the 50%+ correction in the share price as an opportunity.
(Exclusive) The Selloff In EDAP Looks Overdone
May 5th, 2020 · No Comments